Robotic surgery for patients with early stage, oropharyngeal squamous cell cancer is associated with improved health outcomes, including better long-term survival, according to a Cedars-Sinai study published in JAMA Oncology.
Oropharyngeal cancer occurs in the back of the throat and includes the base of the tongue and tonsils.
Transoral robotic surgery is a minimally invasive procedure in which a surgeon uses a computer-enhanced system to guide an endoscope - a flexible tube with a light and camera attached to it - to provide high-resolution, 3D images of the back of the mouth and throat, an area that is difficult to reach with conventional tools.
Two robotically guided instruments, acting as a surgeon's arms, work around corners to safely remove tumours from surrounding tissue.
The Cedars-Sinai retrospective, observational study, which used data from the National Cancer Database, included 9,745 surgical patients - 2,694 of whom underwent transoral robotic surgery between 2010 and 2015.
The authors found that the five-year overall survival rate for patients with early-stage disease who underwent robotic surgery was 84.5%, compared with 80.3% for patients who had non-robotic surgery, after adjusting for differences in health and other characteristics of the two patient groups.
"At a minimum, robotic surgery for oropharyngeal cancer patients seems safe and effective compared to what's been the standard of care for many years," said Zachary S. Zumsteg, MD, assistant professor of Radiation Oncology at Cedars-Sinai, referring to standard surgery, radiation therapy and chemotherapy. He is the study's senior and corresponding author. Anthony T. Nguyen, MD, PhD, a resident in the Department of Radiation Oncology at Cedars-Sinai, is the study's lead author.
Oropharyngeal cancer often is associated with the human papilloma virus, which is believed to cause 70% of oropharyngeal cancers in the United States, according to the Centers for Disease Control and Prevention.
About 3,500 new cases of HPV-associated oropharyngeal cancers are diagnosed in women and about 15,500 in men each year in the U.S.
The Cedars-Sinai study observed that the proportion of patients undergoing transoral robotic surgery for early-stage oropharyngeal cancer increased dramatically after the U.S. Food and Drug Administration approved the surgery for that cancer in 2009 - from 18.3% in 2010 to 35.5% in 2015, according to the researchers' findings.
Additionally, the proportion of facilities performing transoral robotic surgery during that same period more than doubled, from 6.3% to 13.9%.
The nationwide increase in transoral robotic surgery for oropharyngeal cancer prompted the investigators to assess whether the theoretical benefits of robotic surgery for oropharyngeal cancer patients actually provide outcomes that are superior or equivalent to the standard treatments for that cancer type and others.
In addition to increased overall survival rates, the researchers found that robotic surgery was associated with lower rates of positive surgical margins - 12.5% - compared with a rate of 20.3% for non-robotic surgery in patients with oropharyngeal cancer.
Positive surgical margins refer to cancer cells that remain at the edge of tissue that has been surgically removed.
Furthermore, robotic surgery was associated with less use of postoperative chemoradiation, at 28.6%, compared with 35.7% for patients who had non-robotic surgery.
"Our purpose in doing this study was to see how this new technology, which has never been tested in a randomised, controlled trial, has influenced patterns of treatment and outcomes since its FDA approval," Zumsteg said. "There is a learning curve with any new surgical technique, and new ones don't always translate into equal or improved outcomes."
Referring to their study results as "hypothesis-generating," the researchers hope it will inform future randomised, controlled clinical trials," Nguyen said.
"Meanwhile, it's reassuring to our patients that their survival rate is the same if not better with robotic surgery and they have the potential for a better quality of life," Nguyen said.
Source and image credit: Cedars-Sinai Medical Center
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.